Literature DB >> 7782945

Species variation in mechanisms for modulation of growth by beta-adrenergic receptors.

H J Mersmann1.   

Abstract

Beta-adrenergic agonists have been fed to avian and mammalian species to modulate growth. Such treatment produces increased rate of gain, decreased feed consumption, increased skeletal muscle and decreased fat accretion. There is good evidence for the inhibition of adipose tissue lipogenesis and stimulation of lipolysis as well as stimulation of skeletal muscle protein synthesis and inhibition of degradation. Other effects include increased blood flow and modulation of plasma concentration of various hormones. The degree to which each of these effects is observed varies considerably between experiments. Some of the diversity may be explained by species and/or tissue differences in distribution of beta-adrenergic receptor subtypes, in structure and, consequently, in response of receptors and in the pharmacodynamics of the agonist. In addition, several different agonists have been used, adding further complexity. Oversimplification by extrapolation of research observations across species and agonists may confuse attempts to derive mechanisms for the growth modulation effects of beta-adrenergic agonists in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7782945     DOI: 10.1093/jn/125.suppl_6.1777S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  2 in total

1.  Variability in beta-adrenergic receptor population in cultured chicken muscle cells.

Authors:  R B Young; K Y Bridge; J R Vaughn
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-03       Impact factor: 2.416

2.  beta-adrenergic receptor population is up-regulated by increased cyclic adenosine monophosphate concentration in chicken skeletal muscle cells in culture.

Authors:  R B Young; K Y Bridge; J R Vaughn
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.723

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.